It comes as the industry remains divided over the broader applications and outcomes of obesity drugs beyond total weight reduction. Novo Nordisk's hopes of heralding a new era of obesity treatment ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk has won a Committee for Medicinal ... $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq (lorcaserin) and Vivus ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...